Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | $8,614 | $7,739 | $7,052 | $6,614 |
| - Cash | $307 | $464 | $695 | $142 |
| + Debt | $17 | $18 | $18 | $16 |
| Enterprise Value | $8,324 | $7,292 | $6,375 | $6,488 |
| Revenue | $199 | $175 | $161 | $145 |
| % Growth | 13.7% | 8.5% | 11.4% | – |
| Gross Profit | $179 | $160 | $150 | $135 |
| % Margin | 89.8% | 91.3% | 93% | 93.2% |
| EBITDA | -$29 | -$39 | -$28 | -$21 |
| % Margin | -14.6% | -22.1% | -17.1% | -14.4% |
| Net Income | -$17 | -$26 | -$16 | -$15 |
| % Margin | -8.5% | -15% | -10.1% | -10.5% |
| EPS Diluted | 0.56 | -0.25 | -0.16 | -0.16 |
| % Growth | 324% | -56.3% | 0% | – |
| Operating Cash Flow | -$13 | -$27 | $1 | -$34 |
| Capital Expenditures | $0 | -$1 | -$0 | $0 |
| Free Cash Flow | -$13 | -$27 | $0 | -$34 |